Patent · US Active

Tricyclic lactones for treatment of cancer

US9150531B2 · kind B2 · utility

0Cited by

1References

17Claims

0Family size

Assignee

GLACTONE PHARMA DEVELOPMENT AB · SE

Inventors

Ritha Gidlöf · Lund, SE
Martin Johansson · Helsingborg, SE
Olov Sterner · Eidsvold, AU
Eduardo Muñoz · Cordova, ES

Key dates

Filing date	Jul 18, 2011
Grant date	Oct 6, 2015
Priority date	—
Expiry date	Jul 18, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D303/40
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention discloses novel compounds useful for the inhibition of IL-6/STAT signaling and/or PI3K/NF-κB signaling in the treatment of associated diseases or conditions, e.g. cancer. A pharmaceutical composition comprising such novel compounds, its use and a method thereof, is also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.